Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

Keeping Track Feature image

The US Food and Drug Administration balanced another busy week of clearing oncology drug applications with approval actions in contraception (Evofem Biosciences Inc.’s on-demand Phexxi vaginal gel) and neurology (Sunovion Pharmaceuticals Inc.’s sublingual apomorphine film Kynmobi).

Oncology reviewers turned in two first-line approvals in non-small cell lung cancer settings – Takeda Pharmaceutical Co. Ltd.’s Alunbrig...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers